Alternate-Day Buprenorphine Administration. Phase VIII - 9

University of Vermont

Status and phase: Completed; Phase 2

Conditions: Opioid-Related Disorders

Treatments: Drug: Buprenorphine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000227

NIDA-06969-9

R01-06969-9

R01DA006969 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to evaluate open buprenorphine dosing with dose choice.

Sex: All

Ages: 25 to 48 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Please contact site for information.